Overactive Bladder – Epidemiology – Emerging Markets Data
Clarivate Epidemiology’s coverage of overactive bladder (OAB) comprises epidemiological estimates of key patient populations in 14 mature and emerging pharmaceutical markets worldwide. We report the total prevalence of OAB for each country, as well as annualized case counts projected to the national population.
Most patient populations are forecast over a period of 20 years for the major mature pharmaceutical markets and 10 years for the other countries covered in this report.
Clarivate Epidemiology’s OAB forecast will answer the following question:
- How will demographic trends, such as population aging and improving life expectancy, affect the epidemiology of OAB over the forecast period?
All forecast data are available on the Clarivate Insights Platform in tabular format, with options to download to MS Excel. All populations are accompanied by a comprehensive description of the methods and data sources used, with hyperlinks to external sources. A summary evidence table generated as part of our systematic review of the epidemiological literature is provided for full transparency into research and methods.
In addition to the total number of cases for each forecast year, Clarivate Epidemiology provides at least 10 years of forecast data for the following OAB subpopulations:
- Total prevalent cases by subtype.
- Total prevalent cases by severity.
- Total prevalent cases by etiology.
Note: Coverage may vary by country.
Table of contents
- Overactive Bladder - Epidemiology - Emerging Markets Data
- Epidemiology Data
- Methods
- Literature review (studies included in/excluded from the analyses of overactive bladder)
- Total prevalent cases of overactive bladder
- Total prevalent cases of overactive bladder by subtype
- Total prevalent cases of overactive bladder by severity
- Total prevalent cases of overactive bladder by etiology
- Risk / protective factors
- Reference Materials
